Effect of Perioperative Immunosuppressive Medication on Early Outcome in Crohn’s Disease Patients

Indar, Adrian A.; Young-Fadok, Tonia M.; Heppell, Jacques; Efron, Jonathan E.
May 2009
World Journal of Surgery;May2009, Vol. 33 Issue 5, p1049
Academic Journal
The aim of the present study was to examine the early outcome in patients undergoing intestinal resection for Crohn’s disease (CD) while they are receiving perioperative immunosuppressive medication. We reviewed patients with CD undergoing intestinal surgery from 1999 to 2007. Demographics and relevant perioperative information, including medication, were extracted from patient charts. Statistical analysis was performed using Fisher’s exact test. During the course of the study period 112 with Crohn’s disease underwent intestinal resection, and 69 of them were receiving perioperative medication (47, corticosteroids; 39, immunomodulators; and 17, anti-tumor necrosis factor-α antibodies). There were no deaths. Median blood loss was 137 ml. Twenty-two of the patients using perioperative medication (32%) experienced complications, 10 of which were major. The major complications occurred in 3 of the 43 patients (7%) who were not receiving perioperative medications, in 5 of 38 patients (13%) who were receiving one drug, 4 of 28 patients (14%) receiving two drugs, and 1 of 3 patients (33%) receiving three drugs. Thus the occurrence of major complications was not significantly greater in patients receiving perioperative medication. Risk factors for a major complication were intraoperative blood loss >400 ml ( P < 0.003) and emergency surgery ( P < 0.005). The occurrence of complications in Crohn’s disease patients undergoing intestinal resection was not associated with the use of immunosuppressive medication. However, emergency surgery and blood loss were risk factors, and reflect the difficulty of surgery in this group of patients.


Related Articles

  • Management of Postoperative Crohn's Disease. Rodemann, Joseph; Regueiro, Miguel // Inflammatory Bowel Disease Monitor;Apr2009, Vol. 10 Issue 2, p52 

    The majority of patients with Crohn's disease require surgery at some point. Postoperative Crohn's disease recurrence is common after intestinal resection. The optimal management strategy for postoperative recurrence of Crohn's disease is controversial. In the absence of universally adopted...

  • Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease. Viola, Franca; Civitelli, Fortunata; Di Nardo, Giovanni; Barbato, Maria Beatrice; Borrelli, Osvaldo; Oliva, Salvatore; Conte, Francesca; Cucchiara, Salvatore // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2566 

    OBJECTIVES:The use of tumor necrosis factor-alpha (TNF-α) antagonists has changed the therapeutic strategy for Crohn's disease (CD). Adalimumab (ADA), a fully human anti-TNF-α monoclonal antibody, is an effective therapy for patients with CD, both naive patients and those intolerant or...

  • Investigation of TNFA 308G > A and TNFB 252G > A polymorphisms in genetic susceptibility to migraine. Ghosh, Jayashri; Joshi, Gunjan; Pradhan, S.; Mittal, Balraj // Journal of Neurology;Jun2010, Vol. 257 Issue 6, p898 

    We aimed to look for the association of tumor necrosis factor (TNF) gene polymorphisms (TNFA 308G > A, and TNFB 252G > A) in genetic susceptibility to migraine. The pathogenesis of migraine involves many immune-mediated mechanisms in the vascular endothelium. TNF, being a potent immunomodulator...

  • Topical Application of A Novel Immunomodulatory Peptide, RDP58, Reduces Skin Inflammation in the Phorbol Ester-Induced Dermatitis Model. de Vry, Christopher G.; Valdez, Marybeth; Lazarov, Mirella; Muhr, Evelyn; Buelow, Roland; Fong, Timothy; Iyer, Suhasini // Journal of Investigative Dermatology;Sep2005, Vol. 125 Issue 3, p473 

    RDP58 is the first lead compound in a series of immunomodulating decapeptides discovered through activity-based screening and computer-aided, rational design. RDP58 disrupts cellular responses signaled through the Toll-like and tumor necrosis factor (TNF) receptor families and occludes important...

  • Vaccine adjuvants: Tailor-made mast-cell granules. Gunzer, Matthias // Nature Materials;Mar2012, Vol. 11 Issue 3, p181 

    The article presents a study that investigates synthetic submicrometre polymer particles consisting of tumor necrosis factor (TNF) entrapped in a matrix of the polyelectrolytes chitosan and heparin. It is mentioned that the synthetic particles replicate the functions of mast-cell granules,...

  • Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS). Gor, Dennis O.; Xuedong Ding; Qing Li; Sultana, Dilara; Mambula, Salamatu S.; Bram, Richard J.; Greenspan, Neil S. // Biology Direct;2011, Vol. 6 Issue 1, p9 

    Background: B lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor superfamily of ligands that mediates its action through three known receptors. BLyS has been shown to enhance the production of antibodies against heterologous antigens when present at elevated concentrations,...

  • Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. Baughman, Robert P.; Iannuzzi, Michael // BioDrugs;2003, Vol. 17 Issue 6, p425 

    Reports on the importance of tumor necrosis factor (TNF)-alpha, a potent cytokine, in the initiation and perpetuation of inflammation in sarcoidosis, contributing to the initiation of granulomas and the progression of fibrosis. Effect of corticosteroids on TNF; Agents that nonspecifically...

  • The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Morjaria, J. B.; Chauhan, A. J.; Babu, K. S.; Polosa, A.; Davies, D. E.; Holgate, S. T.; Polosa, R // Thorax;Jul2008, Vol. 63 Issue 7, p584 

    Aim: Tumour necrosis factor alpha (TNFalpha) is a cytokine recognised as a therapeutic target in chronic inflammatory diseases.Methods: A randomised, double blind, placebo controlled parallel group trial is reported of etanercept (an IgG1-TNF p75 receptor fusion...

  • Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor--α Antagonists. Tubach, F.; Ravaud, P.; Salmon-Céron, D.; Petitpain, N.; Brocq, O.; Grados, F.; Guillaume, J. C.; Leport, J.; Roudaut, A.; Solau-Gervais, E.; Lemann, M.; Mariette, X.; Lortholary, O. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, pe95 

    Background. Patients treated with tumor necrosis factor-α (TNF-α) antagonists have an increased risk of infection, but infection due to Legionella pneumophila has rarely been described in patients receiving such therapy. Methods. A registry involving 486 clinical departments in France was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics